KPMA backs bioequivalence testing stern measures on generic data fabrication

The Korea Food and Drug Administration says its harsh dispositions to cancel the licenses of pharmaceutical firms' six generic drugs on charge of bioequivalence data fabrication are deemed undisputable.

The health watchdog points out these pharmaceutical manufacturers are solely responsible for the fabrication as it neglected its oversight to thoroughly check whether the marketed generic dru...